geo-d03 dna vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01571960)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- geo-d03 dna vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01909414 | Phase 1 | Jul 24, 2013 | National Institute of Allergy and Infectious Diseases (NIAID), University of Massachusetts |
| NCT01571960 | Phase 1 | Apr 1, 2012 | City of San Francisco, GeoVax, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of Rochester |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2012 |
| City of San Francisco | Government | 1 | 0 | 1 | 2012 |
| GeoVax, Inc. | For profit | 1 | 0 | 1 | 2012 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2012 |
5 organizations
Page 1 / 1